Citius Pharmaceuticals (CTXR) Non-Current Deferred Tax Liability (2016 - 2026)

Citius Pharmaceuticals (CTXR) has 9 years of Non-Current Deferred Tax Liability data on file, last reported at $7.8 million in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 7.75% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 7.75% YoY) and the FY2025 annual result came in at $7.8 million, up 15.74% from the prior year.
• Non-Current Deferred Tax Liability eased to $7.8 million in Q1 2026, from $8.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $8.0 million in Q4 2025 to a low of $5.0 million in Q1 2022.
• A 5-year average of $6.5 million and a median of $6.4 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability changed 0.0% — and 2023, when it climbed 20.22%.
• Tracing CTXR's Non-Current Deferred Tax Liability over 5 years: stood at $5.7 million in 2022, then advanced by 10.09% to $6.3 million in 2023, then advanced by 11.08% to $7.0 million in 2024, then climbed by 15.15% to $8.0 million in 2025, then fell by 2.88% to $7.8 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $7.8 million (Q1 2026), $8.0 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.